AUM Pharmacy
Health Hub
Search Icon

AUM Pharmacy

Hi there!

Hello, Login
All Categories
VisaVisaVisa
fallback

Venozap 37.50 ER Tablet

Prescription Icon
Prescription Required

Marketer

Doxis Laboratories

Salt Composition

Venlafaxine (37.50mg)

Overview Venozap 37.50 ER Tablet

Axilon 37.5mg Extended-Release tablets treat depression and anxiety. This medication modifies brain chemistry, alleviating symptoms like agitation, unease, poor focus, tiredness, perspiration, rapid heartbeat, and racing thoughts. Take Axilon 37.5mg ER with food, consistently at the same time daily for stable blood levels. If a dose is missed, take it immediately upon recall. Complete the prescribed course, even if feeling improved; never abruptly discontinue use, as symptoms may worsen. Potential side effects include queasiness, vomiting, sleep disturbances, reduced appetite, heightened anxiety, constipation, increased sweating, and sexual difficulties. Dizziness and drowsiness are possible; avoid driving or activities demanding concentration until the effects are known. These effects are typically transient and self-limiting. If persistent or troublesome, consult your physician. Prior to commencing Axilon 37.5mg ER, discuss any kidney, heart, or liver issues, or history of seizures with your doctor. Report any unusual mood shifts, worsening depression, or suicidal ideation immediately.

Uses of Venozap 37.50 ER Tablet

Mood disorders encompassing depressive and anxious symptoms

Major Benefits of Venozap 37.50 ER Tablet:

Follow your doctor's instructions precisely regarding the dosage and treatment length for this medication. Ingest the Venozap 37.50 ER Tablet whole; avoid chewing, crushing, or fracturing it. Administer this medication with food.

Common Side effects of Venozap 37.50 ER Tablet:

  • Nausea
  • Vomiting
  • Dizziness
  • Insomnia (difficulty in sleeping)
  • Decreased appetite
  • Anxiety
  • Constipation
  • Increased sweating
  • Sexual dysfunction

How to use Venozap 37.50 ER Tablet:

Consume this medication precisely as your physician directs, adhering to the prescribed dosage and timeframe. Ingest the tablet whole; avoid chewing, crushing, or fracturing it. Venozap 37.50 ER Tablets should be administered with a meal.

How Venozap 37.50 ER Tablet works:

Venozap 37.50 ER tablets elevate brain levels of serotonin and noradrenaline, neurotransmitters crucial for preserving cognitive equilibrium.

SAFETY ADVICE

AlcoholAlcoholUNSAFE

Combining Venozap 37.50 ER Tablet and alcohol is unsafe.

PregnancyPregnancyCONSULT YOUR DOCTOR

Extended-release Venozap 37.50 mg tablets may pose pregnancy risks. While human data is scarce, animal research indicates potential harm to the fetus. A physician will assess the potential advantages against any risks prior to prescribing. Seek medical advice.

Breast feedingBreast feedingCONSULT YOUR DOCTOR

Extended-release Venozap 37.50 mg tablets are likely unsuitable for breastfeeding mothers. Preliminary human data indicates potential transfer to breast milk, posing a risk to the infant. Infants should be observed for signs of lethargy and monitored to ensure appropriate weight increase.

DrivingDrivingUNSAFE

Driving ability may be impaired by Venozap 37.50 ER Tablet side effects. These side effects include dizziness, confusion, and visual disturbances like blurred vision, all of which can negatively impact driving.

KidneyKidneyCAUTION

Patients with kidney impairment should use extended-release Venozap 37.50 mg tablets cautiously, as dose modification may be necessary. Physician consultation is advised.

LiverLiverCAUTION

Patients with hepatic impairment should use Venozap 37.50 ER tablets cautiously; dosage modification may be necessary. Physician consultation is advised.

What if you forget to take Venozap 37.50 ER Tablet :

Should you forget a Venozap 37.50 ER Tablet dose, administer it promptly. Nevertheless, if your next scheduled dose is imminent, omit the missed dose and resume your usual dosing regimen. Avoid taking a double dose.

Facts to Know About Venozap 37.50 ER Tablet

LabelValue
Chemical Category Anise-derived compound
Developing Habits No.
Treatment Category Neuroscience
Actions SNRIs (serotonin-norepinephrine reuptake inhibitors)

FAQs on Venozap 37.50 ER Tablet

Sedation is a possible side effect of Venozap 37.50 ER Tablet. Inform your doctor about any other sleep aids you're using before starting this medication.
Yes. Venozap 37.50 ER Tablet is a psychotropic medication; these medications affect the mind, emotions, and behavior.
Venozap 37.50 ER Tablets are not narcotics. Narcotics are opioid-derived drugs, such as heroin and morphine, that induce sleep.
Venozap 37.50 ER and XR tablets are the same extended-release medication, designed for slow, consistent drug delivery and reduced dosing frequency.
Mirtazapine and Venozap 37.50 ER Tablet taken together pose a serious risk of serotonin syndrome. This life-threatening condition can manifest as agitation, hallucinations, nausea, vomiting, diarrhea, rapid heart rate, fluctuating blood pressure, high fever, and coma.
Concomitant use of citalopram and Venozap 37.50 ER tablets is contraindicated due to their serotonergic effects. This combination risks serotonin syndrome, a potentially fatal condition characterized by agitation, hallucinations, nausea, vomiting, diarrhea, tachycardia, fluctuating blood pressure, hyperthermia, and coma. An alternative medication should be considered.
Venozap 37.50 ER Tablet is removed from the brain by P-glycoprotein. However, some research indicates that both Venozap 37.50 ER Tablet and its metabolite can inhibit this transporter protein.
Following liver metabolism, Venozap 37.50 ER tablets are absorbed into the body via the intestines.
Venozap 37.50 ER tablets treat depression and generalized depressive disorder. Always consult a physician before use.
Treatment with Venozap 37.50 ER Tablets may cause a sustained increase in blood pressure in some patients. Regular blood pressure monitoring is recommended for those taking Venozap 37.50 ER Tablets; dose reduction or treatment discontinuation may be necessary.
Constipation is a known side effect of Venozap 37.50 ER Tablets in some individuals. Increase your fiber intake and fluid consumption. Laxatives may be helpful, and your doctor can advise on prevention and management strategies. If constipation persists or worsens, seek medical attention.
Yes, Venozap 37.50 ER Tablets have been associated with weight loss in some patients. Studies show this weight loss increases with higher doses and longer treatment durations. Talk to your doctor if this concerns you.
Venozap 37.50 ER Tablets are not habit-forming.
Consult your doctor before substituting a tablet for a capsule; the formulations differ, potentially affecting drug release and treatment efficacy. Self-substitution could lead to adverse effects or treatment failure.
Yes, gabapentin and Venozap 37.50 ER tablets may be used together, but only under a doctor's supervision. Concurrent use may increase drowsiness, sleepiness, and impair concentration. Exercise caution.
Desvenlafaxine is the active ingredient in Venozap 37.50 ER Tablet.
Venozap 37.50 ER Tablets are not FDA-approved for fibromyalgia, although some studies suggest potential benefits. Always consult your physician before use.
While not FDA-approved for nerve pain, Venozap 37.50 ER Tablets have shown efficacy in some research studies and are currently used off-label for this purpose.
Venozap 37.50 ER Tablets can alter brain neurotransmitter levels, resulting in reduced appetite; this effect increases with higher doses.
Should you experience side effects such as reduced libido or impotence, consult your doctor to discuss alternative medications. Do not discontinue Venozap 37.50 ER Tablet without medical supervision; doing so may worsen side effects.
Venozap 37.50 ER Tablet
35
MRP 40
12% off